Lantheus Holdings Inc (LNTH)

Shares of Lantheus Holdings Inc (LNTH) dropped by 26.88% from $76.04 to $55.60 in the trading on Monday, December 18, 2023. The reason why LNTH down today is due to the release of new data from a trial of the experimental prostate cancer treatment, Lu-PNT2002, developed by Lantheus Holdings and Point Biopharma Global Inc. The therapy achieved its primary goal with a median progression-free survival of 9.5 months, compared to six months for an alternative treatment. However, investors were disappointed as Novartis AG's Pluvicto, a similar radioligand therapy, showed better results with a median progression-free survival of 12 months in October.